Oncolytics Biotech (ONCY) Net Cash Flow (2009 - 2025)
Oncolytics Biotech (ONCY) posted quarterly Net Cash Flow of $14.1 million for Q4 2025, up 490.9% year-over-year from $2.4 million in Q4 2024, and up 368.88% quarter-over-quarter from $3.0 million in Q3 2025.
Oncolytics Biotech (ONCY) Net Cash Flow (2009 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Net Cash Flow for 17 consecutive years, with $14.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Cash Flow rose 490.9% year-over-year to $14.1 million; the TTM figure through Dec 2025 stood at $25.1 million (up 440.49% YoY), while the FY2025 annual figure was -$6.0 million, up 60.08% from the prior year.
- Net Cash Flow rose to $14.1 million in Q4 2025 per ONCY's latest filing, from $3.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $19.9 million in Q1 2021 and bottomed at -$10.7 million in Q4 2022.
- Historically, Net Cash Flow has averaged $3.7 million across 5 years, with a median of $2.6 million in 2023.
- Annual changes were most pronounced in 2022 — Net Cash Flow sank 10473.09% — and 2023, when it surged 2323.0%.
- Oncolytics Biotech's Net Cash Flow stood at -$100873.5 in 2021, then tumbled by 10473.09% to -$10.7 million in 2022, then soared by 112.0% to $1.3 million in 2023, then jumped by 86.46% to $2.4 million in 2024, then surged by 490.9% to $14.1 million in 2025.
- Business Quant data shows ONCY's Net Cash Flow at $14.1 million in Q4 2025, $3.0 million in Q3 2025, and $3.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Oncolytics Biotech | 96.23 Mn | 96.23 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.10 Mn |
| Dec 31, 2025 | 14.10 Mn |
| Sep 30, 2025 | 3.01 Mn |
| Sep 30, 2025 | 3.01 Mn |
| Jun 30, 2025 | 3.88 Mn |
| Jun 30, 2025 | 3.88 Mn |
| Mar 31, 2025 | 4.10 Mn |
| Mar 31, 2025 | 4.10 Mn |
| Dec 31, 2024 | 2.39 Mn |
| Dec 31, 2024 | 2.39 Mn |
| Sep 30, 2024 | -150,275.95 |
| Sep 30, 2024 | -150,275.95 |
| Jun 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.33 Mn |
| Mar 31, 2024 | 1.08 Mn |
| Mar 31, 2024 | 1.08 Mn |
| Dec 31, 2023 | 1.28 Mn |
| Dec 31, 2023 | 1.28 Mn |
| Sep 30, 2023 | 15.88 Mn |
| Sep 30, 2023 | 15.88 Mn |